Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Glenmark Draws Complete Response Letter for Allergy Spray

  • Post author:Sam
  • Post published:June 28, 2019
  • Post category:Drug Industry Daily

Glenmark Pharmaceuticals said it is “confident” that it can get its investigational allergy spray Ryaltris back on track after the FDA pulled the brakes on its application in the form…

Continue ReadingGlenmark Draws Complete Response Letter for Allergy Spray

Congress Seeks GAO Review of Foreign Drug Inspection Program

  • Post author:Sam
  • Post published:June 28, 2019
  • Post category:Drug Industry Daily

Ongoing recalls of contaminated blood pressure drugs prompted the House Energy and Commerce Committee to call on Friday for a review of the FDA’s foreign drug inspection program. Source: Drug…

Continue ReadingCongress Seeks GAO Review of Foreign Drug Inspection Program

FDA Issues Guidance on Developing Drugs to Treat Epidermolysis Bullosa

  • Post author:Sam
  • Post published:June 28, 2019
  • Post category:Drug Industry Daily

The FDA released final guidance for sponsors of drugs to treat or prevent serious flare-ups of skin disorders known collectively as epidermolysis bullosa (EB). Source: Drug Industry Daily

Continue ReadingFDA Issues Guidance on Developing Drugs to Treat Epidermolysis Bullosa

Pfizer Bags a New Biosimilar — and a Former Commissioner

  • Post author:Sam
  • Post published:June 28, 2019
  • Post category:Drug Industry Daily

In a big week for Pfizer, the world’s second largest drugmaker earned the FDA’s approval for a biosimilar cancer treatment and signed up the agency’s former Commissioner Scott Gottlieb for…

Continue ReadingPfizer Bags a New Biosimilar — and a Former Commissioner

CBER Flags Planned Gene Therapy Guidances for 2019

  • Post author:Sam
  • Post published:June 27, 2019
  • Post category:Drug Industry Daily

CBER released an updated list of guidances it plans to publish this year, including draft recommendations on the following gene therapy topics: Source: Drug Industry Daily

Continue ReadingCBER Flags Planned Gene Therapy Guidances for 2019

FDA Proposes New Rule Formalizing Master Files for BLAs

  • Post author:Sam
  • Post published:June 27, 2019
  • Post category:Drug Industry Daily

The FDA released a proposed rule to codify the use of master files for biologics applications. Source: Drug Industry Daily

Continue ReadingFDA Proposes New Rule Formalizing Master Files for BLAs

FDA Considers How Heart Patients Feel, Function, in New Draft Guidance

  • Post author:Sam
  • Post published:June 27, 2019
  • Post category:Drug Industry Daily

Regulators might be willing to approve heart failure drugs that make patients feel better even if they don’t keep patients out of the hospital — or even alive, the FDA…

Continue ReadingFDA Considers How Heart Patients Feel, Function, in New Draft Guidance

Canada Details New User Fees for Devices

  • Post author:Sam
  • Post published:June 7, 2019
  • Post category:The GMP Letter

Health Canada is increasing fees for device sponsors and will peg ongoing increases to inflation, the agency said in a final report on the planned changes. Source: The GMP Letter

Continue ReadingCanada Details New User Fees for Devices

Senator Demands Answers From Companies Over Duodenoscopes

  • Post author:Sam
  • Post published:June 7, 2019
  • Post category:The GMP Letter

Washington Democratic Sen. Patty Murray is demanding answers from the leaders of three device companies at the center of an ongoing FDA investigation of contaminated duodenoscopes that regulators worry are…

Continue ReadingSenator Demands Answers From Companies Over Duodenoscopes

FDA Issues Alert for Beckman Coulter Blood Analyzers

  • Post author:Sam
  • Post published:June 7, 2019
  • Post category:The GMP Letter

The FDA issued an alert over a recall of Beckman Coulter DxH 800, DxH 600 and DxH 900 blood analyzers, updating an urgent medical device correction letter the company issued…

Continue ReadingFDA Issues Alert for Beckman Coulter Blood Analyzers
  • 1
  • 2
  • 3
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company